Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

1.

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.

Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME; NIAID HIV Vaccine Trials Network.

Clin Trials. 2015 Aug;12(4):394-402. doi: 10.1177/1740774515579165. Epub 2015 Apr 7.

PMID:
25851992
2.

Ebola and quarantine.

Drazen JM, Kanapathipillai R, Campion EW, Rubin EJ, Hammer SM, Morrissey S, Baden LR.

N Engl J Med. 2014 Nov 20;371(21):2029-30. doi: 10.1056/NEJMe1413139. Epub 2014 Oct 27. No abstract available.

3.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.

Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

4.

Patterns of geographic mobility predict barriers to engagement in HIV care and antiretroviral treatment adherence.

Taylor BS, Reyes E, Levine EA, Khan SZ, Garduño LS, Donastorg Y, Hammer SM, Brudney K, Hirsch JS.

AIDS Patient Care STDS. 2014 Jun;28(6):284-95. doi: 10.1089/apc.2014.0028. Epub 2014 May 19.

5.

Cancer-related impairments influence physical activity in uterine cancer survivors.

Hammer SM, Brown JC, Segal S, Chu CS, Schmitz KH.

Med Sci Sports Exerc. 2014 Dec;46(12):2195-201. doi: 10.1249/MSS.0000000000000360.

6.

Structure determination from powder data without prior indexing, using a similarity measure based on cross-correlation functions.

Habermehl S, Mörschel P, Eisenbrandt P, Hammer SM, Schmidt MU.

Acta Crystallogr B Struct Sci Cryst Eng Mater. 2014 Apr;70(Pt 2):347-59. doi: 10.1107/S2052520613033994. Epub 2014 Mar 28.

PMID:
24675604
7.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

8.

Baby steps on the road to HIV eradication.

Hammer SM.

N Engl J Med. 2013 Nov 7;369(19):1855-7. doi: 10.1056/NEJMe1309006. Epub 2013 Oct 23. No abstract available.

PMID:
24152231
9.

207-nm UV light - a promising tool for safe low-cost reduction of surgical site infections. I: in vitro studies.

Buonanno M, Randers-Pehrson G, Bigelow AW, Trivedi S, Lowy FD, Spotnitz HM, Hammer SM, Brenner DJ.

PLoS One. 2013 Oct 16;8(10):e76968. doi: 10.1371/journal.pone.0076968. eCollection 2013.

10.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

11.

A two-dimensional polymer from the anthracene dimer and triptycene motifs.

Bhola R, Payamyar P, Murray DJ, Kumar B, Teator AJ, Schmidt MU, Hammer SM, Saha A, Sakamoto J, Schlüter AD, King BT.

J Am Chem Soc. 2013 Sep 25;135(38):14134-41. doi: 10.1021/ja404351p. Epub 2013 Sep 17.

PMID:
24044739
12.

Translational research insights from completed HIV vaccine efficacy trials.

Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S150-4. doi: 10.1097/QAI.0b013e31829a3985. Review.

PMID:
23764628
13.

CROI 2013: Advances in antiretroviral therapy.

Taylor BS, Wilkin TJ, Shalev N, Hammer SM.

Top Antivir Med. 2013 Apr-May;21(2):75-89. Review.

14.

Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.

Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ.

HIV Clin Trials. 2013 Mar-Apr;14(2):61-7. doi: 10.1310/hct1402-61.

15.

In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.

Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1513-23. doi: 10.1089/AID.2012.0385. Epub 2013 Jun 25.

16.

A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG.

Stat Commun Infect Dis. 2011 Oct;3(1). pii: 1037.

17.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA.

JAMA. 2012 Jul 25;308(4):387-402. doi: 10.1001/jama.2012.7961.

PMID:
22820792
18.

Advances in antiretroviral therapy.

Olender S, Wilkin TJ, Taylor BS, Hammer SM.

Top Antivir Med. 2012 Jun-Jul;20(2):61-86. Review.

19.

Crystal structures of the hydration states of Pigment Red 57:1.

Bekö SL, Hammer SM, Schmidt MU.

Angew Chem Int Ed Engl. 2012 May 7;51(19):4735-8. doi: 10.1002/anie.201109082. Epub 2012 Mar 29. No abstract available.

PMID:
22461339
20.

Advances in antiretroviral therapy.

Taylor B, Olender S, Wilkin TJ, Hammer SM.

Top Antivir Med. 2011 May-Jun;19(2):69-97. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk